HER2 expression and PI3K-Akt pathway alterations in gastric cancer

Yasutaka Sukawa, Hiroyuki Yamamoto, Katsuhiko Nosho, Miki Ito, Hisayoshi Igarashi, Takafumi Naito, Kei Mitsuhashi, Yasutaka Matsunaga, Taiga Takahashi, Masashi Mikami, Yasushi Adachi, Hiromu Suzuki, Yasuhisa Shinomura

研究成果: Article

42 引用 (Scopus)

抄録

The anti-HER2 antibody trastuzumab has led to an era of personalized therapy in gastric cancer (GC). As a result, HER2 expression has become a major concern in GC. HER2 overexpression is seen in 7-34% of GC cases. Trastuzumab is an antibody that targets the HER2 extracellular domain and induces antibody-dependent cellular cytotoxicity and inhibition of the HER2 downstream signals. Mechanisms of resistance to trastuzumab have been reported in breast cancer. There are various mechanisms underlying trastuzumab resistance, such as alterations of HER2 structure or surroundings, dysregulation of HER2 downstream signal effectors and interaction of HER2 with other membrane receptors. The PI3K-Akt pathway is one of the main downstream signaling pathways of HER2. It is well known that PIK3CA mutations and phosphate and tensin homolog (PTEN) inactivation cause over-activation of the downstream signal without an upstream signal activation. Frequencies of PIK3CA mutations and PTEN inactivation have been reported to be 4-25 and 16-77%, respectively. However, little is known about the association between HER2 expression and PI3K-Akt pathway alterations in GC. We have found that HER2 over-expression was significantly correlated with pAkt expression in GC tissues. Furthermore, pAkt expression was correlated with poor prognosis. These results suggest that the PI3K-Akt pathway plays an important role in HER2-positive GC. Moreover, PIK3CA mutations and/or PTEN inactivation might affect the effectiveness of HER2-targeting therapy. Hence, it is necessary to clarify not only HER2 alterations but also PI3K-Akt pathway alterations for HER2-targeting therapy in GC. This review will introduce recent investigations and consider the current status of HER2-targeted therapy for treatment of GC.

元の言語English
ページ(範囲)12-17
ページ数6
ジャーナルDigestion
89
発行部数1
DOI
出版物ステータスPublished - 2014 1
外部発表Yes

Fingerprint

Phosphatidylinositol 3-Kinases
Stomach Neoplasms
Phosphates
Mutation
Antibodies
Mutation Rate
Therapeutics
Anti-Idiotypic Antibodies
Breast Neoplasms
Membranes
Trastuzumab
Tensins

ASJC Scopus subject areas

  • Gastroenterology

これを引用

Sukawa, Y., Yamamoto, H., Nosho, K., Ito, M., Igarashi, H., Naito, T., ... Shinomura, Y. (2014). HER2 expression and PI3K-Akt pathway alterations in gastric cancer. Digestion, 89(1), 12-17. https://doi.org/10.1159/000356201

HER2 expression and PI3K-Akt pathway alterations in gastric cancer. / Sukawa, Yasutaka; Yamamoto, Hiroyuki; Nosho, Katsuhiko; Ito, Miki; Igarashi, Hisayoshi; Naito, Takafumi; Mitsuhashi, Kei; Matsunaga, Yasutaka; Takahashi, Taiga; Mikami, Masashi; Adachi, Yasushi; Suzuki, Hiromu; Shinomura, Yasuhisa.

:: Digestion, 巻 89, 番号 1, 01.2014, p. 12-17.

研究成果: Article

Sukawa, Y, Yamamoto, H, Nosho, K, Ito, M, Igarashi, H, Naito, T, Mitsuhashi, K, Matsunaga, Y, Takahashi, T, Mikami, M, Adachi, Y, Suzuki, H & Shinomura, Y 2014, 'HER2 expression and PI3K-Akt pathway alterations in gastric cancer', Digestion, 巻. 89, 番号 1, pp. 12-17. https://doi.org/10.1159/000356201
Sukawa Y, Yamamoto H, Nosho K, Ito M, Igarashi H, Naito T その他. HER2 expression and PI3K-Akt pathway alterations in gastric cancer. Digestion. 2014 1;89(1):12-17. https://doi.org/10.1159/000356201
Sukawa, Yasutaka ; Yamamoto, Hiroyuki ; Nosho, Katsuhiko ; Ito, Miki ; Igarashi, Hisayoshi ; Naito, Takafumi ; Mitsuhashi, Kei ; Matsunaga, Yasutaka ; Takahashi, Taiga ; Mikami, Masashi ; Adachi, Yasushi ; Suzuki, Hiromu ; Shinomura, Yasuhisa. / HER2 expression and PI3K-Akt pathway alterations in gastric cancer. :: Digestion. 2014 ; 巻 89, 番号 1. pp. 12-17.
@article{5c89f42c401240dc9b4ff1f639317cd3,
title = "HER2 expression and PI3K-Akt pathway alterations in gastric cancer",
abstract = "The anti-HER2 antibody trastuzumab has led to an era of personalized therapy in gastric cancer (GC). As a result, HER2 expression has become a major concern in GC. HER2 overexpression is seen in 7-34{\%} of GC cases. Trastuzumab is an antibody that targets the HER2 extracellular domain and induces antibody-dependent cellular cytotoxicity and inhibition of the HER2 downstream signals. Mechanisms of resistance to trastuzumab have been reported in breast cancer. There are various mechanisms underlying trastuzumab resistance, such as alterations of HER2 structure or surroundings, dysregulation of HER2 downstream signal effectors and interaction of HER2 with other membrane receptors. The PI3K-Akt pathway is one of the main downstream signaling pathways of HER2. It is well known that PIK3CA mutations and phosphate and tensin homolog (PTEN) inactivation cause over-activation of the downstream signal without an upstream signal activation. Frequencies of PIK3CA mutations and PTEN inactivation have been reported to be 4-25 and 16-77{\%}, respectively. However, little is known about the association between HER2 expression and PI3K-Akt pathway alterations in GC. We have found that HER2 over-expression was significantly correlated with pAkt expression in GC tissues. Furthermore, pAkt expression was correlated with poor prognosis. These results suggest that the PI3K-Akt pathway plays an important role in HER2-positive GC. Moreover, PIK3CA mutations and/or PTEN inactivation might affect the effectiveness of HER2-targeting therapy. Hence, it is necessary to clarify not only HER2 alterations but also PI3K-Akt pathway alterations for HER2-targeting therapy in GC. This review will introduce recent investigations and consider the current status of HER2-targeted therapy for treatment of GC.",
keywords = "Akt, Gastric cancer, HER2, Phosphate and tensin homolog, PI3K, PIK3CA, Trastuzumab",
author = "Yasutaka Sukawa and Hiroyuki Yamamoto and Katsuhiko Nosho and Miki Ito and Hisayoshi Igarashi and Takafumi Naito and Kei Mitsuhashi and Yasutaka Matsunaga and Taiga Takahashi and Masashi Mikami and Yasushi Adachi and Hiromu Suzuki and Yasuhisa Shinomura",
year = "2014",
month = "1",
doi = "10.1159/000356201",
language = "English",
volume = "89",
pages = "12--17",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - HER2 expression and PI3K-Akt pathway alterations in gastric cancer

AU - Sukawa, Yasutaka

AU - Yamamoto, Hiroyuki

AU - Nosho, Katsuhiko

AU - Ito, Miki

AU - Igarashi, Hisayoshi

AU - Naito, Takafumi

AU - Mitsuhashi, Kei

AU - Matsunaga, Yasutaka

AU - Takahashi, Taiga

AU - Mikami, Masashi

AU - Adachi, Yasushi

AU - Suzuki, Hiromu

AU - Shinomura, Yasuhisa

PY - 2014/1

Y1 - 2014/1

N2 - The anti-HER2 antibody trastuzumab has led to an era of personalized therapy in gastric cancer (GC). As a result, HER2 expression has become a major concern in GC. HER2 overexpression is seen in 7-34% of GC cases. Trastuzumab is an antibody that targets the HER2 extracellular domain and induces antibody-dependent cellular cytotoxicity and inhibition of the HER2 downstream signals. Mechanisms of resistance to trastuzumab have been reported in breast cancer. There are various mechanisms underlying trastuzumab resistance, such as alterations of HER2 structure or surroundings, dysregulation of HER2 downstream signal effectors and interaction of HER2 with other membrane receptors. The PI3K-Akt pathway is one of the main downstream signaling pathways of HER2. It is well known that PIK3CA mutations and phosphate and tensin homolog (PTEN) inactivation cause over-activation of the downstream signal without an upstream signal activation. Frequencies of PIK3CA mutations and PTEN inactivation have been reported to be 4-25 and 16-77%, respectively. However, little is known about the association between HER2 expression and PI3K-Akt pathway alterations in GC. We have found that HER2 over-expression was significantly correlated with pAkt expression in GC tissues. Furthermore, pAkt expression was correlated with poor prognosis. These results suggest that the PI3K-Akt pathway plays an important role in HER2-positive GC. Moreover, PIK3CA mutations and/or PTEN inactivation might affect the effectiveness of HER2-targeting therapy. Hence, it is necessary to clarify not only HER2 alterations but also PI3K-Akt pathway alterations for HER2-targeting therapy in GC. This review will introduce recent investigations and consider the current status of HER2-targeted therapy for treatment of GC.

AB - The anti-HER2 antibody trastuzumab has led to an era of personalized therapy in gastric cancer (GC). As a result, HER2 expression has become a major concern in GC. HER2 overexpression is seen in 7-34% of GC cases. Trastuzumab is an antibody that targets the HER2 extracellular domain and induces antibody-dependent cellular cytotoxicity and inhibition of the HER2 downstream signals. Mechanisms of resistance to trastuzumab have been reported in breast cancer. There are various mechanisms underlying trastuzumab resistance, such as alterations of HER2 structure or surroundings, dysregulation of HER2 downstream signal effectors and interaction of HER2 with other membrane receptors. The PI3K-Akt pathway is one of the main downstream signaling pathways of HER2. It is well known that PIK3CA mutations and phosphate and tensin homolog (PTEN) inactivation cause over-activation of the downstream signal without an upstream signal activation. Frequencies of PIK3CA mutations and PTEN inactivation have been reported to be 4-25 and 16-77%, respectively. However, little is known about the association between HER2 expression and PI3K-Akt pathway alterations in GC. We have found that HER2 over-expression was significantly correlated with pAkt expression in GC tissues. Furthermore, pAkt expression was correlated with poor prognosis. These results suggest that the PI3K-Akt pathway plays an important role in HER2-positive GC. Moreover, PIK3CA mutations and/or PTEN inactivation might affect the effectiveness of HER2-targeting therapy. Hence, it is necessary to clarify not only HER2 alterations but also PI3K-Akt pathway alterations for HER2-targeting therapy in GC. This review will introduce recent investigations and consider the current status of HER2-targeted therapy for treatment of GC.

KW - Akt

KW - Gastric cancer

KW - HER2

KW - Phosphate and tensin homolog

KW - PI3K

KW - PIK3CA

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84893054197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893054197&partnerID=8YFLogxK

U2 - 10.1159/000356201

DO - 10.1159/000356201

M3 - Article

C2 - 24458107

AN - SCOPUS:84893054197

VL - 89

SP - 12

EP - 17

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 1

ER -